Case Report
Antiretroviral therapy-induced Leber’s hereditary optic neuropathy
Submitted: 12 December 2014 | Published: 23 May 2014
About the author(s)
Anand Moodley, Department of Neurology, Grey’s Hospital, Pietermaritzburg and University of KwaZulu-Natal, Durban, South Africa, South AfricaSudika Bhola, Department of Neurology, Grey’s Hospital, Pietermaritzburg and University of KwaZulu-Natal, Durban, South Africa
Fierdoz Omar, Chemical Pathology Laboratory, Groote Schuur Hospital; National Health Laboratory Service and University of Cape Town, South Africa
Jade Mogambery, Department of Medicine, Grey’s Hospital, Pietermaritzburg, South Africa
Full Text:
PDF (118KB)Abstract
Optic neuropathy in HIV-infected patients results from the HIV infection itself, post-infectious auto-immune disease, opportunistic infections and drugs. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and stavudine have known mitochondrial toxicity and can cause mitochondrial myopathies, neuropathies, hyperlactataemia, and can induce mitochondrial genetic disorders. Individuals with the mutation for Leber’s hereditary optic neuropathy (LHON), a mitochondrial disorder, are usually asymptomatic but develop visual loss when exposed to external triggers such as smoking. We report on two HIV-infected patients with LHON mutations (m.14484T>C and m.11778G>A) who developed profound visual loss with antiretroviral therapy. We postulate that the phenotypic expression of LHON in these genetically predisposed individuals was triggered by NRTI drugs lamivudine and tenofovir when used in combination, despite their relatively weak mitochondrial toxic effects.
Keywords
Metrics
Total abstract views: 4020Total article views: 2658
Crossref Citations
1. Long-term screening for primary mitochondrial DNA variants associated with Leber hereditary optic neuropathy: incidence, penetrance and clinical features
Rosetta Marotta, Judy Chin, Maria Chiotis, Neil Shuey, Steven J. Collins
Mitochondrion vol: 54 first page: 128 year: 2020
doi: 10.1016/j.mito.2020.08.007